Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity.
Aminoacid
Arginase
Arginine
Autochthonous
Immunocompetent
MDSC
Metabolic checkpoint
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
06 02 2019
06 02 2019
Historique:
received:
01
08
2018
accepted:
09
01
2019
entrez:
8
2
2019
pubmed:
8
2
2019
medline:
1
4
2020
Statut:
epublish
Résumé
Tumor orchestrated metabolic changes in the microenvironment limit generation of anti-tumor immune responses. Availability of arginine, a semi-essential amino acid, is critical for lymphocyte proliferation and function. Levels of arginine are regulated by the enzymes arginase 1,2 and nitric oxide synthase (NOS). However, the role of arginase activity in lung tumor maintenance has not been investigated in clinically relevant orthotopic tumor models. RNA sequencing (RNA-seq) of sorted cell populations from mouse lung adenocarcinomas derived from immunocompetent genetically engineered mouse models (GEMM)s was performed. To complement mouse studies, a patient tissue microarray consisting of 150 lung adenocarcinomas, 103 squamous tumors, and 54 matched normal tissue were stained for arginase, CD3, and CD66b by multiplex immunohistochemistry. Efficacy of a novel arginase inhibitor compound 9 in reversing arginase mediated T cell suppression was determined in splenocyte ex vivo assays. Additionally, the anti-tumor activity of this compound was determined in vitro and in an autochthonous immunocompetent Kras Analysis of RNA-seq of sorted myeloid cells suggested that arginase expression is elevated in myeloid cells in the tumor as compared to the normal lung tissue. Accordingly, in the patient samples arginase 1 expression was mainly localized in the granulocytic myeloid cells and significantly elevated in both lung adenocarcinoma and squamous tumors as compared to the controls. Our ex vivo analysis demonstrated that myeloid derived suppressor cell (MDSC)s cause T cell suppression by arginine depletion, and suppression of arginase activity by a novel ARG1/2 inhibitor, compound 9, led to restoration of T cell function by increasing arginine. Treatment of Kras We show that arginase expression is elevated in mouse and patient lung tumors. In a KRAS
Sections du résumé
BACKGROUND
Tumor orchestrated metabolic changes in the microenvironment limit generation of anti-tumor immune responses. Availability of arginine, a semi-essential amino acid, is critical for lymphocyte proliferation and function. Levels of arginine are regulated by the enzymes arginase 1,2 and nitric oxide synthase (NOS). However, the role of arginase activity in lung tumor maintenance has not been investigated in clinically relevant orthotopic tumor models.
METHODS
RNA sequencing (RNA-seq) of sorted cell populations from mouse lung adenocarcinomas derived from immunocompetent genetically engineered mouse models (GEMM)s was performed. To complement mouse studies, a patient tissue microarray consisting of 150 lung adenocarcinomas, 103 squamous tumors, and 54 matched normal tissue were stained for arginase, CD3, and CD66b by multiplex immunohistochemistry. Efficacy of a novel arginase inhibitor compound 9 in reversing arginase mediated T cell suppression was determined in splenocyte ex vivo assays. Additionally, the anti-tumor activity of this compound was determined in vitro and in an autochthonous immunocompetent Kras
RESULTS
Analysis of RNA-seq of sorted myeloid cells suggested that arginase expression is elevated in myeloid cells in the tumor as compared to the normal lung tissue. Accordingly, in the patient samples arginase 1 expression was mainly localized in the granulocytic myeloid cells and significantly elevated in both lung adenocarcinoma and squamous tumors as compared to the controls. Our ex vivo analysis demonstrated that myeloid derived suppressor cell (MDSC)s cause T cell suppression by arginine depletion, and suppression of arginase activity by a novel ARG1/2 inhibitor, compound 9, led to restoration of T cell function by increasing arginine. Treatment of Kras
CONCLUSIONS
We show that arginase expression is elevated in mouse and patient lung tumors. In a KRAS
Identifiants
pubmed: 30728077
doi: 10.1186/s40425-019-0504-5
pii: 10.1186/s40425-019-0504-5
pmc: PMC6366094
doi:
Substances chimiques
Arginase
EC 3.5.3.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
32Subventions
Organisme : NCI NIH HHS
ID : R01 CA205150
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA195740
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA215075
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA070907
Pays : United States
Organisme : NCI NIH HHS
ID : K08 CA163677
Pays : United States
Références
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
J Exp Med. 2010 Oct 25;207(11):2439-53
pubmed: 20876310
Oncotarget. 2015 Nov 17;6(36):38816-26
pubmed: 26452035
Front Immunol. 2011 Jul 21;2:29
pubmed: 22566819
J Immunother Cancer. 2013 Jul 15;1:10
pubmed: 24829747
J Clin Gastroenterol. 1994 Jan;18(1):84-5
pubmed: 8113593
Nature. 2012 Mar 28;483(7391):603-7
pubmed: 22460905
Cancer Res. 2016 Mar 1;76(5):999-1008
pubmed: 26833127
J Immunother Cancer. 2016 Feb 16;4:4
pubmed: 26885366
Int J Cancer. 2008 Sep 1;123(5):1108-16
pubmed: 18528866
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Clin Cancer Res. 2016 Aug 1;22(15):3713-7
pubmed: 27252413
Nat Biotechnol. 2010 May;28(5):511-5
pubmed: 20436464
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi. 1987 Nov;20(4):279-89
pubmed: 3449318
Cancer Discov. 2014 Jun;4(6):662-673
pubmed: 24675041
Cancer Res. 2016 Jun 1;76(11):3189-99
pubmed: 27197187
EBioMedicine. 2017 Apr;18:56-61
pubmed: 28356222
Surg Today. 2003;33(9):655-61
pubmed: 12928840
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
Proc Natl Acad Sci U S A. 2014 Apr 15;111(15):5664-9
pubmed: 24706787
Blood. 2013 Aug 1;122(5):749-58
pubmed: 23733335
Cancer Discov. 2012 Aug;2(8):722-35
pubmed: 22822050
J Thorac Oncol. 2017 Aug;12(8):1268-1279
pubmed: 28483607
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
Lung Cancer. 2013 Sep;81(3):468-474
pubmed: 23850196
J Immunol. 2008 Oct 15;181(8):5791-802
pubmed: 18832739
J Immunother Cancer. 2018 Jan 23;6(1):8
pubmed: 29357948
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Am J Clin Nutr. 2006 Feb;83(2):508S-512S
pubmed: 16470022
Carcinogenesis. 2001 Nov;22(11):1863-9
pubmed: 11698350
J Clin Invest. 2013 Apr;123(4):1580-9
pubmed: 23454751
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
J Clin Oncol. 2015 Jun 20;33(18):2004-12
pubmed: 25897158
Cancer Res. 2013 May 1;73(9):2737-42
pubmed: 23423980
Mol Cell. 2000 Aug;6(2):269-79
pubmed: 10983975
Cancer Res. 2015 Aug 1;75(15):3043-53
pubmed: 26054597
J Hematol Oncol. 2008 Sep 25;1:14
pubmed: 18817562
Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):721s-726s
pubmed: 17255300
Blood. 2007 Feb 15;109(4):1568-73
pubmed: 17023580
Clin Chim Acta. 2003 Feb;328(1-2):105-11
pubmed: 12559605
Front Immunol. 2014 Oct 27;5:533
pubmed: 25386179
Cancer Immunol Immunother. 2012 Jul;61(7):1019-31
pubmed: 22146893
Nat Med. 2015 Jun;21(6):591-600
pubmed: 25962123
Mol Immunol. 2008 Dec;46(2):258-68
pubmed: 18824264
Crit Rev Oncog. 2013;18(1-2):135-51
pubmed: 23237556
Front Immunol. 2013 Sep 17;4:278
pubmed: 24062745
N Engl J Med. 2013 Jun 20;368(25):2385-94
pubmed: 23724913
Cancer Discov. 2015 Aug;5(8):860-77
pubmed: 26069186
J Med Chem. 2013 Mar 28;56(6):2568-80
pubmed: 23472952
Cancer Res. 2002 Oct 1;62(19):5443-50
pubmed: 12359751
J Immunother Cancer. 2017 Dec 19;5(1):101
pubmed: 29254508
Nat Biotechnol. 2015 Apr;33(4):321-2
pubmed: 25850038
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
J Exp Med. 2005 Oct 3;202(7):931-9
pubmed: 16186186
Nat Med. 2018 Aug;24(8):1277-1289
pubmed: 29988129
BMC Cancer. 2017 Feb 16;17(1):141
pubmed: 28209123
N Engl J Med. 2004 May 20;350(21):2129-39
pubmed: 15118073
Br J Pharmacol. 2009 Oct;158(3):638-51
pubmed: 19764983
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Cancer Res. 2004 Aug 15;64(16):5839-49
pubmed: 15313928
Nat Commun. 2018 May 18;9(1):1988
pubmed: 29777108
Adv Immunol. 2006;90:51-81
pubmed: 16730261
Immunol Cell Biol. 2003 Aug;81(4):247-65
pubmed: 12848846
Cancer J. 2012 Mar-Apr;18(2):153-9
pubmed: 22453017
Lung Cancer. 2017 Apr;106:1-7
pubmed: 28285682
Cell. 2015 Sep 10;162(6):1257-70
pubmed: 26343581
Front Immunol. 2017 Feb 07;8:93
pubmed: 28223985
Am J Clin Nutr. 2005 May;81(5):1142-6
pubmed: 15883440